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Objectives: Widespread antimicrobial resistance often limits the availability of therapeutic options to only a few
last-resort drugs that are themselves challenged by emerging resistance and adverse side effects. Apramycin,
an aminoglycoside antibiotic, has a unique chemical structure that evades almost all resistance mechanisms
including the RNA methyltransferases frequently encountered in carbapenemase-producing clinical isolates.
This study evaluates the in vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-
resistant Enterobacteriaceae and Acinetobacter baumannii, and provides a rationale for its superior antibacterial
activity in the presence of aminoglycoside resistance determinants.
Methods: A thorough antibacterial assessment of apramycin with 1232 clinical isolates from Europe, Asia, Africa
and South America was performed by standard CLSI broth microdilution testing. WGS and susceptibility testing
with an engineered panel of aminoglycoside resistance-conferring determinants were used to provide a mech-
anistic rationale for the breadth of apramycin activity.
Results: MIC distributions and MIC90 values demonstrated broad antibacterial activity of apramycin against
Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., Morganella morganii, Citrobacter freundii, Providencia
spp., Proteus mirabilis, Serratia marcescens and A. baumannii. Genotypic analysis revealed the variety of
aminoglycoside-modifying enzymes and rRNA methyltransferases that rendered a remarkable proportion of
clinical isolates resistant to standard-of-care aminoglycosides, but not to apramycin. Screening a panel of engi-
neered strains each with a single well-defined resistance mechanism further demonstrated a lack of cross-
resistance to gentamicin, amikacin, tobramycin and plazomicin.
Conclusions: Its superior breadth of activity renders apramycin a promising drug candidate for the treatment of
systemic Gram-negative infections that are resistant to treatment with other aminoglycoside antibiotics.
Introduction
Infectious diseases, particularly those caused by MDR pathogens,
carbapenemase-producing Enterobacteriaceae (CPE) and
carbapenemase-producing Acinetobacter baumannii (CPA),
remain a major cause of morbidity and mortality worldwide.1–4
Widespread antimicrobial resistance often limits the availability of
therapeutic options to only a very few efficacious antibiotics.5,6
Last-resort drugs such as tigecycline and colistin are themselves
increasingly challenged by emerging resistance7 and
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compromised by significant adverse side effects.3,8 New thera-
peutic treatment options are therefore urgently needed.
Aminoglycoside antibiotics inhibit the essential process of pro-
tein biosynthesis9,10 by targeting the bacterial ribosome, one of
the most effective targets in anti-infective history when looking
back at seven decades of clinical track record.11 Aminoglycoside
antibiotics are recognized for rapid bactericidal activity in serious
systemic infections.12 Clinically relevant aminoglycoside antibiot-
ics, however, are equally and increasingly challenged by emerging
resistance13 due to aminoglycoside-modifying enzymes, and RNA
methyltransferases frequently encountered in carbapenem-
resistant isolates.14
Apramycin is a monosubstituted deoxystreptamine that differs
in its chemical structure from clinically relevant aminoglycoside
antibiotics that are all disubstituted (Figure 1). Its unique structure
renders the apramycin molecule intrinsically resilient to almost all
resistance determinants typically found in MDR and XDR Gram-
negative bacteria.15–17 Apramycin has also been demonstrated to
be of lower toxicity than other aminoglycosides of the disubsti-
tuted deoxystreptamine drug class.18
Here we report on a broad in vitro activity of apramycin against
a variety of clinical isolates from patients in Europe, Asia, Africa
and South America, including MDR, CPE and CPA. Furthermore, we
elucidated the genotype of selected clinical isolates and tested
engineered resistant strains to provide a mechanistic rationale for
the superior spectrum of apramycin activity when compared with
clinical benchmark drugs.
Materials and methods
Bacterial isolates
A total of 1132 Enterobacteriaceae and 100 A. baumannii clinical isolates
were investigated in this study. The isolates were collected between 2014
and 2017 by clinical laboratories in Europe, Asia, Africa and South America,
and donated without patient information.
Antimicrobial agents
Antimicrobial standards were obtained from the European Pharmacopoeia
with microbiological potency values provided in each certificate of analysis.
A microbiological potency value was not provided for apramycin sulphate
purchased from Sigma-Aldrich. The lot-specific assay of active free base
was therefore accurately determined by quantitative NMR as 554lg of
apramycin free base per mg of sulphate salt ‘as is’. Stock solutions were pre-
pared according to CLSI guideline M07.19
Aminoglycoside susceptibility testing
CLSI broth microdilution reference methodology M0719 was used to deter-
mine MICs of antimicrobial agents. The MIC values were assessed by visual
inspection with the help of an MIC 2000 Illuminated viewer (Dynatech,
Kloten, Switzerland). All susceptibility testing assays were quality controlled
against Escherichia coli ATCC 25922. The MIC quality control range for apra-
mycin was determined as 2–8 mg/L (modal MIC of 4 mg/L). For all other
drugs, the quality control was run against CLSI performance standards for
antimicrobial susceptibility testing (M100-S25). The most recent EUCAST in-
terpretive guidelines (www.eucast.org/clinical_breakpoints) were used to
determine EUCAST breakpoints for the categorical interpretations of sus-
ceptibility and resistance for gentamicin, tobramycin, kanamycin and ami-
kacin. For the non-clinical aminoglycoside apramycin, the MIC distributions
presented in this study were used to define the following tentative ECOFFs
(epidemiological cut-off values) as interpretative criteria of susceptibility
and resistance: 4 mg/L for K. pneumoniae and Enterobacter spp., 8 mg/L for
E. coli and 16 mg/L for A. baumannii.
Whole-genome sequencing
Clinical isolates of interest were analysed by MALDI-TOF and submitted to
IIT Biotech GmbH, Bielefeld, Germany, for WGS and an ARG-ANNOT data-
base search for antibiotic resistance genes. MALDI-TOF analysis, WGS and
bioinformatics annotation of resistance genes were performed as described
previously.20–22
Construction of a strain panel expressing
aminoglycoside resistance determinants
The amino acid sequence of all relevant aminoglycoside resistance genes
was identified by reference genes listed in Table S1 (available as
Supplementary data at JAC Online) and cloned downstream of an insulated
constitutive promoter of defined promoter strength.23 Each resistance cas-
sette was then cloned into a low-copy plasmid with a pBR322 origin of repli-
cation, an ampicillin resistance cassette and a T7 terminator sequence
downstream of the resistance gene. Chemically competent E. coli DH10B-
derived TOP10 cells (Invitrogen) were transformed with the resulting ex-
pression plasmids, colony purified, quality-controlled by sequence analysis
and antimicrobial susceptibility assessed by standard broth microdilution
assays.19
Results
Broad antibacterial activity of apramycin
Apramycin demonstrated broad activity against all bacterial spe-
cies tested, including MDR, CPE and CPA clinical isolates, collected
between 2014 and 2017 in Europe, Asia, Africa and South America
(Table 1).
Apramycin exhibited significantly better antimicrobial activity
against E. coli, Klebsiella pneumoniae, Enterobacter spp.,
Providencia spp., Morganella morganii, Citrobacter freundii, Proteus
mirabilis, Serratia marcescens and clinical isolates of the
A. baumannii complex than the clinical standard-of-care amino-
glycosides gentamicin and amikacin (Table 1). An apramycin con-
centration of 8 mg/L inhibited 98% of all Enterobacteriaceae
isolates tested. An apramycin concentration of 16 mg/L inhibited
97% of all A. baumannii isolates tested. At the level of individual
Enterobacteriaceae species, an apramycin concentration of 4 mg/L
inhibited 99% of K. pneumoniae and 93% of Enterobacter iso-
lates. An apramycin concentration of 8 mg/L inhibited 99% of all
E. coli, 98% of C. freundii, 96% of Providencia spp., 92% of S. mar-
cescens, 97% of M. morganii and 100% of P. mirabilis clinical iso-
lates (Table 1). In comparison, the MIC90 of amikacin and
gentamicin was .64 mg/L for most of the Enterobacteriaceae
species tested (Table 1). The epidemiological distribution of MIC
values highlighted the uncompromised in vitro activity of apra-
mycin against clinical isolates of Enterobacteriaceae and A. bau-
mannii (Figure 2 and Figures S1 and S2).
High activity of apramycin against CPE and A. baumannii
In addition to looking at all isolates collectively, we also analysed
the activity of apramycin against the carbapenemase-producing
subpopulation of isolates representing the most urgent unmet
medical need.4 A total of 406 carbapenemase-producing E. coli,
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K. pneumoniae, Enterobacter, C. freundii and Providencia spp. isolates
and 17 CPA were investigated in this study. Apramycin concentra-
tions of 4 and 8 mg/L inhibited 93% and 97% of all CPE isolates, re-
spectively. A concentration of 16 mg/L was required to inhibit 94% of
CPA isolates (Table 1). In comparison, gentamicin and amikacin
showed little activity against these isolates. In plotting the MIC distri-
bution of apramycin for only CPE and CPA, the superiority of apramy-
cin over clinical benchmark aminoglycosides became even more
apparent (Figure 2). Against individual CPE species, apramycin inhib-
ited 97% of K. pneumoniae and 94% of C. freundii clinical isolates at
4 mg/L, and 94% of E. coli and 93% of Enterobacter clinical isolates
at 8 mg/L. In comparison, gentamicin and amikacin were found to
be inactive against a remarkable proportion of carbapenemase-pro-
ducing E. coli, K. pneumoniae, Enterobacter, C. freundii and
Providencia spp. clinical isolates (Figure 2). The higher activity of apra-
mycin against individual CPE species became particularly apparent
when plotting the MIC distribution (Figure S1).
Importantly, and in contrast to the clinically approved antibiot-
ics gentamicin, kanamycin, tobramycin, amikacin, plazomicin and
meropenem,24–27 apramycin was active against E. coli isolates
that were characterized by WGS as encoding carbapenemases
NDM-1, OXA-23 and IMP-1, which are the main causes of carbape-
nem resistance in CPE strains (Table 2).28,29 Apramycin was like-
wise active against K. pneumoniae strains encoding
Figure 1. Structural rationale for the activity of apramycin in the presence of aminoglycoside resistance determinants. The chemical structures of
monosubstituted (a) versus disubstituted (b) deoxystreptamine antibiotics indicating the reactive groups that are modified by acetyltransferases
(AACs), phosphotransferases (APHs) and nucleotidyltransferases (ANTs). Molecular modelling of the RMTase-catalysed N7-methylation of G1405 (red
sphere) onto the crystal structure of ribosome-bound apramycin (PDB entry 4AQY) reveals no clash of the methyl group with the 4-monosubstituted
2-DOS apramycin (c). Molecular modelling of the G1405 methylation onto the crystal structure of ribosome-bound gentamicin (PDB entry 4V53)
reveals considerable clash with ring III of 4,6-disubstituted 2-DOS (d). Nucleotides of the 16S rRNA are shown in pale yellow, and apramycin and gen-
tamicin are shown in yellow and teal, respectively. The E. coli nucleotide numbering is used throughout.
Apramycin activity against CPE and MDR bacteria JAC
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carbapenemases KPC-2, OXA-181, OXA-232 and OXA-48 (Table 2),
and against E. coli strains harbouring the plasmid-mediated colis-
tin resistance gene, mcr-1.30
Genotypic rationale for superior antibacterial activity
To assess the potency of apramycin against MDR bacteria, we
compared the susceptibility and MIC distribution of MDR versus
non-MDR clinical isolates of E. coli, K. pneumoniae and E. cloacae
against a panel of aminoglycoside antibiotics. Clinical isolates in
this analysis were classified as MDR if expressing resistance to at
least three out of the following five drug classes: third-generation
cephalosporins, quinolones, aminoglycosides, carbapenems and a
b-lactam antibiotic with a b-lactamase inhibitor, namely piperacil-
lin/tazobactam.31 The distribution of MICs for MDR clinical isolates
was shifted to higher MIC values for the analysed benchmark ami-
noglycoside antibiotics, amikacin, gentamicin, kanamycin and
tobramycin, when compared with non-MDR clinical isolates, but
not for apramycin (Figure S3).
WGS of MDR clinical isolates of E. coli, E. cloacae and K. pneumo-
niae revealed the genotypes associated with the phenotypic resist-
ance profiles of the analysed clinical isolates. The identified
genotypes corresponded closely to the resistance phenotypes pre-
dicted by the aminoglycoside antibiogram (Figure 1). A broad var-
iety of aminoglycoside resistance determinants and combinations
thereof were identified in the genomes of the sequenced MDR clin-
ical isolates including several distinct subtypes of acetyltransfer-
ases (AACs), phosphotransferases (APHs), nucleotidyltransferases
(ANTs) and 16S rRNA methyltransferases (RMTases) (Table 3).
The predominant resistance mechanisms identified were those
facilitated by the acetyltransferases AAC(60) and AAC(3), which
accounted for the majority of phenotypic non-susceptibility to
gentamicin, tobramycin, amikacin and kanamycin (Table 3). The
nucleotidyltransferase ANT(20 0), phosphotransferase APH(30) and
the RMTase-encoding genes armA, rmtB and rmtC were also found
in clinical E. coli, K. pneumoniae, Enterobacter and A. baumannii iso-
lates (Table 3). As predicted, the presence of these antibiotic resist-
ance genes in the genomes of the analysed MDR clinical isolates
did not negatively impact the antibacterial activity of apramycin.
In conclusion, although many of the MDR clinical isolates analysed
were resistant to benchmark aminoglycoside antibiotics, they
retained a susceptible phenotype to apramycin when applying the
ECOFF of 8 mg/L for E. coli, 4 mg/L for K. pneumoniae and
Enterobacter spp., and 16 mg/L for A. baumannii (Table 3).
Apramycin evades almost all aminoglycoside resistance
mechanisms
The high genotypic diversity and the presence of multiple antibiotic
resistance determinants within individual isolates may in part blur
a more mechanistic correlation between phenotypic resistance
and individual resistance genes. Key resistance genes were there-
fore cloned into a DH10B-derived E. coli lab strain to allow
promoter-controlled expression of individual resistance genes in
an otherwise isogenic background. This enabled elucidation of the
apramycin activity in the presence of individual and well-defined
resistance genes including AACs, APHs, ANTs and RMTases. This
analysis revealed high activity of apramycin against all known re-
sistance mechanisms, with the exception of AAC(3)-IV (Table 4). In
contrast, the clinical aminoglycosides gentamicin, amikacin, tobra-
mycin and amikacin were each inactivated by a variety of resist-
ance mechanisms as expected.32–34 Susceptibility to amikacin was
reduced in the presence of AAC(60) and some subtypes of APH(30)
and, similarly to plazomicin, was fully abolished in the presence of
RMTases. When comparing the resistance profile of plazomicin
with that of amikacin, it became apparent that susceptibility to
plazomicin was retained in the presence of AAC(60) and APH(30),
but at the cost of lower susceptibility to plazomicin than amikacin
in the presence of AAC(20) and APH(20 0). The superiority of apramy-
cin to other aminoglycosides was particularly remarkable for
RMTases. Engineered E. coli strains expressing armA, rmtB, rmtC or
rmtF genes were highly resistant (MIC .64 mg/L) to all other ami-
noglycoside antibiotics tested, including plazomicin, while remain-
ing susceptible to apramycin (Table 4). The only resistance
determinant investigated in this study that rendered the host
E. coli cells non-susceptible to apramycin was the aminoglycoside
3-N-acetyltransferase subtype IV [AAC(3)-IV] (Table 4), a resist-
ance mechanism that was previously known to confer apramycin
resistance.35
Discussion
The results presented in this study clearly demonstrate that apramy-
cin has a broad antibacterial activity against a variety of clinical
Table 1. MIC90 of apramycin in comparison with gentamicin and amika-
cin against clinical isolates of Enterobacteriaceae and A. baumannii iso-
lated between 2014 and 2017
MIC90 (mg/L)
Species No. APR GEN AMK
Enterobacteriaceae (all) 1132 8 .64 .64
Escherichia coli 250 8 .64 .64
Klebsiella pneumoniae 372 4 .64 .64
Enterobacter spp. 179 4 .64 .64
Morganella morganii 37 8 .64 4
Citrobacter freundii 131 8 .64 .64
Providencia spp. 80 8 .64 .64
Proteus mirabilis 32 8 .64 .64
Serratia marcescens 51 8 .64 .64
CPE only (all) 406 4 .128 .128
Escherichia coli 74 8 .128 .128
Klebsiella pneumoniae 236 4 .128 .128
Enterobacter spp. 48 8 .128 .128
Citrobacter freundii 48 4 .128 .128
A. baumannii 100 16 .64 .64
CPA only 17 16 .256 .256
Geographic origin
Europe 799 8 .64 .64
Asia 240 8 .256 .256
Africa 107 8 .256 .256
South America 86 4 .256 .256
APR, apramycin; AMK, amikacin; GEN, gentamicin; CPE, carbapenemase-
producing Enterobacteriaceae; CPA, carbapenemase-producing
A. baumannii.
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isolates, including MDR, CPE and CPA clinical isolates of diverse
geographic origin (Table 1). This is consistent with previous reports,
which showed that the vast majority of the analysed CPE
clinical isolates from the USA, the UK and China were more suscep-
tible to apramycin than to other aminoglycosides.16,28,36 Our analysis
provides strong evidence that the high susceptibility to apramycin is
a widespread phenomenon and not geographically restricted.
Apramycin retains significant activity against a broad spectrum
of MDR and XDR clinical isolates, including those with NDM-1,
IMP-1, OXA-23, OXA-48, OXA-181, OXA-232 and KPC-2 genotypes
(Tables 1 and 2).28,29 Previously, it was shown that in comparison
with amikacin, gentamicin and tobramycin, apramycin is highly
active against MDR, XDR and pan-drug-resistant (PDR) clinical iso-
lates that include A. baumannii and P. aeruginosa.15 Furthermore,
our results also demonstrate uncompromised activity of apramy-
cin against E. coli clinical isolates harbouring the plasmid-borne re-
sistance gene mcr-130 (Table 2), which confers resistance to the
last-resort drug colistin.
45 60
50
40
30
20
10
0
40
35
30
Pe
rc
en
t 
is
ol
at
es
Pe
rc
en
t 
is
ol
at
es
25
20
15
10
5
0
80 70 70
60
50
40
30
20
10
0
60
50
40
30
20
10
0
70
60
50
40
Pe
rc
en
t 
is
ol
at
es
30
20
10
0
60 40
35
30
25
20
15
10
5
0
45
40
35
30
25
20
15
10
5
0
50
40
30
Pe
rc
en
t 
is
ol
at
es
Pe
rc
en
t 
is
ol
at
es
20
10
0
90 40 45
40
35
30
25
20
15
10
5
0
35
30
25
20
15
10
5
0
80
70
60
50
40
30
20
10
0
≤0.5 ≤0.5 1 2 4 8 16 32 64 >64 ≤0.5 1 2 4 8 16 32 64 >641 2 4 8 16 32 64 >64
≤0.5 1 2 4 8 16 32 64 >64
≤0.5 1 2 4
MIC (mg/L)
8 16 32 64 >64 ≤0.5 1 2 4
MIC (mg/L)
8 16 32 64 >64 ≤0.5 1 2 4
MIC (mg/L)
8 16 32 64 >64
≤0.5 1 2 4 8 16 32 64 >64 ≤0.5 1 2 4 8 16 32 64 >64
≤0.5 1 2 4 8
MIC (mg/L)
16 32 64
APR GEN AMK
>64 ≤0.5 1 2 4 8
MIC (mg/L)
Enterobacteriaceae (n = 1132)(a)
(b)
CPE (n = 406)
E. coli (n = 250) K. pneumoniae (n = 372) Enterobacter spp. (n = 179)
M. morganii (n = 37) C. freundii (n = 131) Providencia spp. (n = 80)
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Figure 2. MIC distribution of apramycin in comparison with gentamicin and amikacin. (a) MIC distribution for Enterobacteriaceae clinical isolates of di-
verse geographic origin collected between 2014 and 2017 (left), and a subset of only carbapenemase-producing Enterobacteriaceae (CPE, right). (b) MIC
distribution for Enterobacteriaceae and A. baumannii at the genus or species level. APR, apramycin; AMK, amikacin; GEN, gentamicin; CPE, carbapene-
mase-producing Enterobacteriaceae. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
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Perhaps the most striking observation is that the presence of
various antibiotic resistance-conferring genes, such as those
encoding aminoglycoside-modifying enzymes and RMTases, did
not adversely affect the distribution of apramycin MICs in the ana-
lysed clinical isolate panels. Apramycin remained active against
E. coli harbouring various individual aminoglycoside resistance
determinants, including those which rendered the host E. coli cells
resistant against all other antibiotics tested (Tables 3 and 4). The
only mechanisms found to induce significant resistance to apra-
mycin was that of the acetyltransferase AAC(3)-IV (Table 4), which
has previously been identified as a pre-determinant of resistance
to apramycin and other aminoglycosides.37
Regio-specific acetylation of the 3-amino group is catalysed by
a family of acetyltransferases that for the most part do not seem
to recognize apramycin as a substrate. To date, AAC(3)-IV is the
only subtype known to acetylate apramycin efficiently. Acetylation
at C3 not only replaces an amino group with a less basic amide, but
may also prevent its binding to the drug target site by means of a
steric clash with the phosphate backbone of 16S rRNA (Figure S4).
Of 1232 clinical isolates tested in this study, 4 isolates (,0.5%)
were found to be resistant to all antibiotics tested including apramy-
cin. The fact that apramycin resistance was found to be rare in a
relevant panel of clinical isolates suggests a very high (.99%) prob-
ability of coverage in empirical treatment of MDR pathogens. WGS
of the four isolates resistant to apramycin revealed the presence of
a variety of resistance genes including aac(3)-IV (Table S2), which
was in agreement with the genotypic prediction inferred from the
results with engineered E. coli strains (Table 4). The fact that resist-
ance to apramycin was exclusively associated with an aac(3)-IV-
positive genotype in all cases suggests feasibility of a PCR detection
kit as a more rapid diagnostic than bacterial culture or WGS. Among
over a thousand clinical isolates from across the globe included
herein, no other apramycin resistance determinants were found.
A literature search for additional mechanisms of apramycin re-
sistance suggested acetylation of the 1-amino group as another
possible mechanism of apramycin resistance.38,39 However, little
clinical or other evidence has since corroborated the hypothesis.
Putative AAC(1) enzymes were found to acetylate aminoglycoside
antibiotics inconsistently.40 Structural modelling suggests that the
drug-binding pocket can accommodate an acetamide at C1
Table 2. Antibiotic susceptibility of selected genotypes of E. coli and K. pneumoniae clinical isolates isolated between 2014 and 2017
MIC (mg/L)
Organism Characteristic APR GEN KAN TOB AMK PLZ MEM
E. coli NDM-1 8 .128 .128 .128 .128 .128 .128
IMP-1 4 32 128 32 8 4 8
MCR-1 2–4 2 .128 0.5 1 2 0.125
OXA-23 8 64 .128 16 4 2 8
K. pneumoniae KPC-2 2 128 .128 .128 .128 .128 128
OXA-181 2 64 128 64 8 1–2 4
OXA-232 2 .128 .128 .128 .128 .128 128
OXA-48 2 128 .128 .128 .128 1 64
APR, apramycin; GEN, gentamicin; KAN, kanamycin; TOB, tobramycin; AMK, amikacin; PLZ, plazomicin; MEM, meropenem.
Table 3. Phenotypes associated with the predominant aminoglycoside
resistance determinants found in the analysed bacterial strains by WGS
Resistance phenotype
Genotype APR GEN AMK KAN TOB
Escherichia coli
AAC(3)-II S R S I I
AAC(60)-I S S I R R
AAC(60)-I ANT(20 0) S R R R R
AAC(60)-I AAC(3)-II S R I R R
rmtB AAC(3)-II APH(30) S R R R R
Klebsiella pneumoniae
ANT(20 0) S I I R I
AAC(3)-II APH(30) S R S R I
AAC(60)-I APH(30) S S I R R
AAC(60)-I AAC(3)-II S R I R R
AAC(60)-I AAC(3)-II APH(30) S R I R R
rmtB AAC(60)-I AAC(3)-II S R R R R
Enterobacter cloacae
ANT(20 0) S I I I I
AAC(60)-I AAC(3)-II S R S R R
AAC(60)-I ANT(20 0) S I I R R
AAC(60)-I AAC(3)-V ANT(20 0) S R I R R
AAC(60)-I AAC(3)-V APH(30) S R R R R
rmtC AAC(60)-I AAC(3)-II S R R R R
Acinetobacter baumannii
armA S R R R R
AAC(60)-I S I R R R
APH(30)-I armA S R R R R
AAC(60)-I APH(30) S I R R R
AAC(3)-I armA S R R R R
APH(30)-VI AAC(3)-I S R R R S
APH(30)-VI AAC(3)-I ANT(20 0) S R R R R
AAC(60)-I AAC(3)-I APH(30) S R R R R
APR, apramycin; GEN, gentamicin; AMK, amikacin; KAN, kanamycin; TOB,
tobramycin.
In the case of apramycin, ECOFFs have been used as interpretative
criteria.
Juhas et al.
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without a prohibitive steric clash, unlike acetylation at C3 discussed
above (Figure S4). This is in agreement with the fact that aminogly-
cosides such as amikacin, arbekacin or plazomicin, with the bulkier
L-4-amino-2-hydroxybutyramide amide group at C1, are accepted
by the drug-binding pocket without significant loss of activity
when compared with the parent amines. Any loss of activity on
acetamide formation at the 1-position would therefore be likely to
arise owing to the loss of the basic amine (unlike amikacin, arbeka-
cin and plazomicin in which the functionalized amide group itself
carries a basic amine). The existence of such AAC(1) resistance
mechanisms, however, has yet to be confirmed independently.
Phylogenetic alignment of amino acid sequences revealed a very
high sequence homology of putative AAC(1) sequences with
AAC(3)-I proteins (Figure S5). Further studies are needed to re-
analyse the functional conversion of aminoglycosides in the pres-
ence of AAC(1) proteins.
The high activity of apramycin against MDR, CPE and CPA clinical
isolates is owing to the ability of apramycin both to evade
aminoglycoside-modifying enzymes and to bind to a methylated
drug target site.18 Drug target methylation at ribosomal site N7-
G1405 by RMTases encoded by armA and rmtC, and related anti-
biotic resistance-conferring enzymes effectively distorts the bind-
ing pocket for clinically approved aminoglycoside antibiotics,
including plazomicin (Figure 1).41,42 Consequently, although
retaining antibiotic activity against many aminoglycoside-modify-
ing enzymes, plazomicin is inactive against drug-resistant clinical
isolates encoding RMTases.43 Methylation of N7-G1405 is fre-
quently encountered in CPE clinical isolates17,36,44–47 and is there-
fore often associated with the resistance of CPE to all of the
clinically relevant aminoglycoside antibiotics. In contrast, the bind-
ing and activity of apramycin are not prevented by methylation of
N7-G1405.18 The crystal structure of apramycin bound to its target
site (Figure 1) reveals sufficient space to accommodate methyla-
tion of N7-G1405, whereas otherwise it results in a steric clash with
the glycosidic ring at C6 in standard-of-care aminoglycosides and
plazomicin, all of which are 4,6-disubstituted deoxystrept-
amines.18,48 This ultimately leads to uncompromised activity of
apramycin against a broad spectrum of pathogenic bacteria,
including CRE and A. baumannii.
WGS of clinical A. baumannii isolates tested in this study
revealed a relatively high incidence (44%) of armA-positive iso-
lates. Because ArmA-mediated methylation inside the drug-bind-
ing pocket does not obstruct the binding of apramycin, the MIC
distribution of apramycin was found to be superior to that of other
aminoglycoside antibiotics for clinical isolates of the A. baumannii
complex (Figure 2b).
Although some of the other clinically relevant aminoglycoside
antibiotics, such as amikacin, tobramycin and gentamicin, have
previously been successfully applied in the treatment of CPE infec-
tions either alone or in combination with other antimicrobial
agents,49,50 increasing RMTase-mediated resistance represents a
challenge for treatment of CPE and CPA bacterial infections, in par-
ticular in Southern Europe and in low- and middle-income coun-
tries in South America, Africa and Asia. The intrinsic resilience of
apramycin to common mechanisms of aminoglycoside resistance
including 16S rRNA-modifying enzymes translates into a superior
spectrum of activity that comprises highly drug-resistant Gram-
negative organisms and hence a possible therapeutic remedy for
this issue. Collectively, our results are in agreement with previous
reports suggesting the potential of apramycin.15,28,51
In the present study, preliminary ECOFFs were used as inter-
pretative criteria because the pharmacokinetics (PK), probabil-
ity of target attainment and, therefore, clinical breakpoints for
apramycin are currently unknown. Preliminary (and as yet un-
published) data on the apramycin PK in various animal species
suggest a PK profile that resembles that of other aminoglyco-
side antibiotics. Further preclinical evaluation is required to
study the in vivo efficacy and the PK/pharmacodynamics of
apramycin, which will be important in assessing the clinical po-
tential of apramycin in the treatment of MDR Gram-negative
bacterial infections in humans.
Apramycin may also represent a promising lead scaffold for fur-
ther derivatization, taking advantage of the various beneficial fea-
tures of apramycin including its exquisite selectivity for the
bacterial over the eukaryotic cytosolic and mitochondrial ribo-
somes.52–54 Together with its low inherent toxicity reported
earlier,18 apramycin and apramycin-like monosubstituted deoxy-
streptamines may represent a promising new subclass of amino-
glycoside antibiotics for further optimization and development.
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